Whether your team is developing diagnostics, validating therapeutic targets, testing vaccines, or any other studies involving the novel coronavirus SARS-CoV-2, Science Exchange’s provider network can accelerate any type of study, some of which we have highlighted on this page.
All Science Exchange service providers work under existing contracts that protect client IP and confidentiality, so mission-critical projects can be initiated without delay.
On Science Exchange, you can view service providers in each category ranked by number of completed orders, responsiveness, and customer ratings. Click the links to view the top-rated providers and request a quote. Your project could start as soon as 2-3 days.
Animal models of infection, vaccination, specific immunity, and more — to support discovery, ADMET or other preclinical studies of COVID-19 therapeutics and vaccines.
Blood, plasma, throat swabs, serum, sputum, organ tissue samples — to support discovery of COVID-19 biomarkers or risk factors.
Virus purification, antiviral assays, pseudovirus assays, testing viral infectivity and analyzing host-pathogen interactions — including BSL-3 labs and live-virus work for COVID-19 research.
DNA vaccine and gene therapy vectors, antigen screens, efficacy and safety testing, production and formulation — to support vaccine development for COVID-19.
Critical SARS-CoV-2 antigens prepared and purified for interaction studies, antibody development for COVID-19 research and diagnostics.
Isolation of antibodies from SARS-Cov-2 infected individuals, screening for antibodies that recognize viral epitopes, antibody purification, antibody panels, and more.
Next-gen sequencing and RNA sequencing services for SARS-CoV-2 — to support detection and characterization in your COVID-19 research.
Measurement of targets in swab or other samples, copy number calculation, and off-the-shelf kits — to support detection of SARS-Cov-2 and transcription profiling.
ELISAs for COVID-19 related antigens, multiplex assays, COVID-19 cytokine panels — to characterize presence of proteins and understand the immune response to infection.
<back to top>
BIOQUAL, Inc is developing in vivo SARS-CoV-2 animal infection models, including rodent, ferret and NHP. They maintain labs and vivariums under BSL-2 and BSL-3, as well as a CDC-approved BSL-3 Special Agent containment facility. Contact them below to discuss testing your vaccine or therapeutic candidates in their efficacy and safety studies.
With speciality in the infectious disease space, iProcess Global Research Inc. can obtain blood, plasma and swab samples from COVID-19 patients through their global network of CAP certified labs and clinicians. Contact them below to source HBS samples in support your COVID-19 research.
Testing of prospective inhibitors with Retrovirox’s CPE-based assay against OC43 is a valuable tool for preliminary screens of potential inhibitors of SARS-CoV-2. Assays are also available to specifically evaluate inhibition of viral entry of SARS-CoV-2. Contact them below to learn more about their COVID-19 assays.
<back to top>